GlassScriptPhysician profile
Gregory C Trolley
NPI 1609019652
$6,966.91
in general payments reported to CMS, 2019-2025
46 companies · $1,742 in 2025
The $1,742 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $374 · 2021: $710 · 2022: $716 · 2023: $1,449 · 2024: $1,314 · 2025: $1,742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,504.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $726.07 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $590.38 | 2019-2025 | |
| Abbvie INC. | $506.91 | 2021-2025 | Ubrelvy, Duopa, Botox |
| Lundbeck LLC | $497.89 | 2019-2025 | Vyepti, Rexulti |
| Ucb, INC. | $391.87 | 2019-2025 | Zilbrysq, Briviact, Rystiggo |
| Lilly USA, LLC | $378.38 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Teva Pharmaceuticals USA, INC. | $335.29 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Eisai INC. | $298.46 | 2023-2025 | |
| Biogen, INC. | $281.03 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Neurocrine Biosciences, INC. | $267.00 | 2022-2023 | Ingrezza, Ongentys |
| Celgene Corporation | $264.21 | 2022-2025 | Zeposia |
| Ge Healthcare | $172.63 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $159.46 | 2019-2025 | Nuplazid, Daybue |
| Genentech USA, INC. | $153.32 | 2022-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Allergan, INC. | $151.18 | 2019-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Trolley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.